<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03692598</url>
  </required_header>
  <id_info>
    <org_study_id>MID-002</org_study_id>
    <nct_id>NCT03692598</nct_id>
  </id_info>
  <brief_title>Study of Transcatheter Tricuspid Annular Repair</brief_title>
  <acronym>STTAR</acronym>
  <official_title>Study of Transcatheter Tricuspid Annular Repair</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Micro Interventional Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Micro Interventional Devices</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety and performance of the MIA Minimally&#xD;
      Invasive Annuloplasty Device in patients with chronic functional tricuspid regurgitation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to evaluate the safety and performance of the MIA Minimally&#xD;
      Invasive Annuloplasty Device in patients with chronic functional tricuspid regurgitation. The&#xD;
      study is a prospective, multi-center safety and performance study. Enrolled subjects will be&#xD;
      assessed for clinical follow-up at 1 month, 6 months, and 1 year post implant procedure.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 2016</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major Adverse Events</measure>
    <time_frame>30 days</time_frame>
    <description>The percentage of participants with Major Adverse Events within 30 days of the procedure: death, Q-wave myocardial infarction, cardiac tamponade, cardiac surgery for failed MIA implantation, or stroke</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction in tricuspid regurgitation at 30 days</measure>
    <time_frame>30 days</time_frame>
    <description>The reduction in the degree of tricuspid regurgitation compared to baseline measured post-procedure, at post-operative hospital discharge and at 1 month post-operative. Ability to reduce tricuspid regurgitation by at least 1 degree by means of quantitative echocardiographic parameters</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events (SAEs) and Serious Adverse Device Events (SADE)</measure>
    <time_frame>3 months</time_frame>
    <description>The percentage of participants with Serious Adverse Events (SAEs) and Serious Adverse Device Events (SADE) within 6 months of the procedure will be compared to the literature.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction in tricuspid regurgitation</measure>
    <time_frame>3 months</time_frame>
    <description>Assessment in the degree of Tricuspid Regurgitation at 3 months compared to baseline Ability to maintain improvement in tricuspid regurgitation with respect to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Measurement</measure>
    <time_frame>3 months</time_frame>
    <description>Change in quality of life questionnaire (Minnesota Living with Heart Failure Questionnaire) compared to baseline at 6 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Tricuspid Regurgitation</condition>
  <arm_group>
    <arm_group_label>MIA Surgical</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible patients will receive implantation of MIA implants deployed using the MIA, Minimally Invasive Annuloplasty Device - Surgical from an open surgical approach</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MIA Percutaneous</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible patients will receive implantation of MIA implants deployed using the MIA, Minimally Invasive Annuloplasty Device - Percutaneous from a transcatheter approach</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MIA, Minimally Invasive Annuloplasty Device - Surgical</intervention_name>
    <description>Eligible patients will receive implantation of MIA implants deployed using the MIA, Minimally Invasive Annuloplasty Device from an open surgical approach</description>
    <arm_group_label>MIA Surgical</arm_group_label>
    <other_name>MIA-S</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MIA, Minimally Invasive Annuloplasty Device - Percutaneous</intervention_name>
    <description>Eligible patients will receive implantation of MIA implants deployed using the MIA, Minimally Invasive Annuloplasty Device from a percutaneous approach</description>
    <arm_group_label>MIA Percutaneous</arm_group_label>
    <other_name>MIA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Chronic functional tricuspid regurgitation (FTR) with a minimum of moderate tricuspid&#xD;
             regurgitation (2-4)&#xD;
&#xD;
          2. Age≥18 and ≤85 years old&#xD;
&#xD;
          3. New York Heart Association (NYHA) Class II, III or ambulatory IV&#xD;
&#xD;
          4. Left ventricular ejection fraction (LVEF) ≥30%&#xD;
&#xD;
          5. Undergoing cardiac surgical procedure with the planned use of cardiopulmonary bypass&#xD;
             (surgical arm only)&#xD;
&#xD;
          6. Functional tricuspid valve regurgitation pathology with a structurally normal valve;&#xD;
             and tricuspid valve annular diameter ≥ 40 mm (or 21 mm/m2) and ≤55 mm (or 29 mm/m2) or&#xD;
             2-4 + FTR&#xD;
&#xD;
          7. Patient provides written Informed Consent before any study-specific tests or&#xD;
             procedures are performed&#xD;
&#xD;
          8. Patient is willing and able to comply with all specified study evaluations&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or lactating female&#xD;
&#xD;
          2. Severe uncontrolled hypertension (SBP ≥ 180 mmHg and/or DBP ≥ 110 mmHg)&#xD;
&#xD;
          3. Previous tricuspid valve repair or replacement&#xD;
&#xD;
          4. Myocardial Infarction or known unstable angina within the 30-days prior to the index&#xD;
             procedure&#xD;
&#xD;
          5. Any PCI within 30 days prior to the index procedure or planned 3 months post the index&#xD;
             procedure&#xD;
&#xD;
          6. Life expectancy of less than 12-months&#xD;
&#xD;
          7. Severe right heart dysfunction&#xD;
&#xD;
          8. Pulmonary hypertension with PA mean 2/3 rd MAP&#xD;
&#xD;
          9. Active systemic infection&#xD;
&#xD;
         10. Pericardial infection&#xD;
&#xD;
         11. Any clinical evidence that the investigator feels would place the patient at increased&#xD;
             risk with the deployment of the device&#xD;
&#xD;
         12. Co-morbid conditions that place the subject at an unacceptable surgical risk (e.g.&#xD;
             severe chronic obstructive pulmonary disease, hepatic failure, cardiac disease,&#xD;
             autoimmune disorders or conditions of severe immunosuppression)&#xD;
&#xD;
         13. Untreated coronary artery disease (CAD) requiring revascularisation unless CABG&#xD;
             procedure is concomitant with MIA tricuspid annular repair (surgical arm only)&#xD;
&#xD;
         14. Haemodynamic instability: systolic blood pressure &lt;90mmHg without reduction of&#xD;
             afterload, shock, need for inotropic medication or IABP&#xD;
&#xD;
         15. Active peptic ulcer or gastrointestinal (GI) bleeding in the past 3 months&#xD;
&#xD;
         16. Cerebrovascular event within the past 6 months&#xD;
&#xD;
         17. History of mitral/tricuspid endocarditis within the last 12 months&#xD;
&#xD;
         18. Organic tricuspid disease&#xD;
&#xD;
         19. Contraindication or known allergy to device's components, aspirin, anti-coagulation&#xD;
             therapy or contrast media that cannot be adequately premeditated&#xD;
&#xD;
         20. Known alcohol or drug abuser&#xD;
&#xD;
         21. Currently participating in the study of an investigational drug or device&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kestutis Rucinskas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vilnius University Hospital, Santariskiu Klinikos</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Willard Hennemann, PhD</last_name>
    <phone>215 600-1273</phone>
    <email>bhennemann@microinterventional.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeremy L West</last_name>
    <phone>6127566791</phone>
    <email>jwest@microinterventional.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steen H Poulsen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Semmelweis University, Heart and Vascular Center</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bela Merkely</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre of Cardiology, Pauls Stradins Clinical University Hospital</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrejs Erglis</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lithuanian University of Health Sciences</name>
      <address>
        <city>Kaunas</city>
        <zip>50009</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rimantas Benetis</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vilnius University Hospital Santariskiu Klinikos</name>
      <address>
        <city>Vilnius</city>
        <zip>08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kestutis Rucinskas, MD</last_name>
      <email>Kestutis.Rucinskas@santa.lt</email>
    </contact>
    <contact_backup>
      <last_name>Vilius Janusauskus, MD</last_name>
      <email>Vilius.Janusauskas@santa.lt</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The Cardinal Stefan Wyszyński Institute of Cardiology</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcin Demkow</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Hungary</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 2, 2016</study_first_submitted>
  <study_first_submitted_qc>September 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2018</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tricuspid Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

